DK3805248T5 - Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf - Google Patents
Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf Download PDFInfo
- Publication number
- DK3805248T5 DK3805248T5 DK20200642.5T DK20200642T DK3805248T5 DK 3805248 T5 DK3805248 T5 DK 3805248T5 DK 20200642 T DK20200642 T DK 20200642T DK 3805248 T5 DK3805248 T5 DK 3805248T5
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- procedure
- concentration
- therapeutic products
- therapeutic
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
- B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/16—Flow or flux control
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60909204P | 2004-09-09 | 2004-09-09 | |
US11/220,362 US20060051347A1 (en) | 2004-09-09 | 2005-09-06 | Process for concentration of antibodies and therapeutic products thereof |
EP10009914.2A EP2292636B9 (en) | 2004-09-09 | 2005-09-08 | Process for concentration of antibodies and therapeutic products thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DK3805248T3 DK3805248T3 (da) | 2023-04-03 |
DK3805248T5 true DK3805248T5 (da) | 2023-04-24 |
Family
ID=35996499
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05806393.4T DK1786830T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf |
DK22178117.2T DK4108259T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK20200642.5T DK3805248T5 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK10009914.2T DK2292636T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK22178156.0T DK4104859T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05806393.4T DK1786830T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til koncentration af antistoffer og terapeutiske produkter deraf |
DK22178117.2T DK4108259T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10009914.2T DK2292636T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
DK22178156.0T DK4104859T3 (da) | 2004-09-09 | 2005-09-08 | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf |
Country Status (33)
Country | Link |
---|---|
US (6) | US20060051347A1 (da) |
EP (5) | EP4108259B1 (da) |
JP (2) | JP5210633B2 (da) |
KR (2) | KR101528970B1 (da) |
CN (3) | CN101056885B (da) |
AR (1) | AR050641A1 (da) |
AU (1) | AU2005285243C1 (da) |
BR (1) | BRPI0515649B8 (da) |
CA (1) | CA2577317C (da) |
DK (5) | DK1786830T3 (da) |
EC (1) | ECSP077282A (da) |
ES (4) | ES2975166T3 (da) |
FI (3) | FI2292636T3 (da) |
GT (1) | GT200500254A (da) |
HK (2) | HK1101249A1 (da) |
HU (2) | HUE065025T2 (da) |
IL (2) | IL181372A (da) |
LT (4) | LT4104859T (da) |
MA (1) | MA28991B1 (da) |
MX (2) | MX2007002812A (da) |
MY (2) | MY162525A (da) |
NO (1) | NO333660B1 (da) |
NZ (1) | NZ553239A (da) |
PE (1) | PE20060816A1 (da) |
PL (4) | PL3805248T3 (da) |
PT (4) | PT2292636T (da) |
RU (1) | RU2390524C2 (da) |
SG (1) | SG177161A1 (da) |
SI (4) | SI2292636T1 (da) |
TN (1) | TNSN07069A1 (da) |
TW (1) | TWI372630B (da) |
WO (1) | WO2006031560A2 (da) |
ZA (1) | ZA200701626B (da) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
NZ576986A (en) | 2004-01-30 | 2010-12-24 | Shire Pharmaceuticals Ireland Ltd | Production and purification of recombinant arylsulfatase A |
MXPA06012990A (es) | 2004-05-12 | 2007-02-12 | Baxter Int | Microesferas de acidos nucleicos, produccion y suministro de las mismas. |
JP2007537288A (ja) | 2004-05-12 | 2007-12-20 | バクスター インターナショナル インコーポレイテッド | オリゴヌクレオチド含有マイクロスフェア、1型糖尿病を処置する医薬の製造のための、その使用 |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
US20080311078A1 (en) | 2005-06-14 | 2008-12-18 | Gokarn Yatin R | Self-Buffering Protein Formulations |
EP2583744A1 (en) * | 2006-03-31 | 2013-04-24 | Genencor International, Inc. | Permeate product of tangential flow filtration process |
ES2744499T3 (es) | 2006-04-04 | 2020-02-25 | Chiesi Farm Spa | Un proceso para la concentración de un polipéptido |
EP2527364A1 (en) | 2007-03-29 | 2012-11-28 | Abbott Laboratories | Crystalline anti-human IL-12 antibodies |
WO2009010269A1 (en) | 2007-07-17 | 2009-01-22 | F.Hoffmann-La Roche Ag | Variable tangential flow filtration |
WO2009068282A1 (en) * | 2007-11-29 | 2009-06-04 | F. Hoffmann-La Roche Ag | Immunoglobulin aggregates |
US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
TWI661833B (zh) * | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
ES2406029T3 (es) | 2008-04-15 | 2013-06-05 | Grifols Therapeutics Inc. | Ultrafiltración/diafiltración en dos fases |
NZ589297A (en) * | 2008-05-15 | 2011-12-22 | Health L P W | Process for producing milk fractions rich in secretory immunoglobulins |
US20110236391A1 (en) * | 2008-12-09 | 2011-09-29 | Hanns-Christian Mahler | Method for obtaining an excipient-free antibody solution |
WO2010090864A2 (en) * | 2009-01-21 | 2010-08-12 | Smartflow Technologies, Inc. | Optimization of separation for viscous suspensions |
AU2010221156A1 (en) * | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
US9586180B2 (en) * | 2009-03-24 | 2017-03-07 | Wyeth Llc | Membrane evaporation for generating highly concentrated protein therapeutics |
MY157239A (en) | 2009-05-27 | 2016-05-13 | Baxalta Inc | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
JP5697268B2 (ja) * | 2009-09-29 | 2015-04-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | バッファー溶質のろ過前調整方法 |
EP3715369A1 (en) * | 2009-10-01 | 2020-09-30 | F. Hoffmann-La Roche AG | Multistep final filtration |
KR101912169B1 (ko) | 2010-02-04 | 2018-10-26 | 체에스엘 베링 아게 | 면역글로불린 제제 |
CA2976671C (en) | 2010-03-01 | 2021-01-12 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
US10336992B2 (en) | 2011-07-08 | 2019-07-02 | Shire Human Genetic Therapies, Inc. | Methods for purification of arylsulfatase A |
KR101993488B1 (ko) | 2011-09-01 | 2019-06-26 | 추가이 세이야쿠 가부시키가이샤 | 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법 |
WO2013096791A1 (en) | 2011-12-23 | 2013-06-27 | Genentech, Inc. | Process for making high concentration protein formulations |
US20130281355A1 (en) | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
JP2016504344A (ja) * | 2012-12-28 | 2016-02-12 | ノヴォ ノルディスク アー/エス | 高温デッドエンド抗体ろ過 |
JP6427502B2 (ja) | 2013-01-09 | 2018-11-21 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | アリールスルファターゼaの精製方法 |
DE102013001628A1 (de) | 2013-01-30 | 2014-07-31 | Fresenius Medical Care Deutschland Gmbh | Verfahren zur Bereitstellung eines Konzentrats |
CN106794424B (zh) | 2014-05-13 | 2020-10-30 | 美国安进公司 | 用于过滤器和过滤过程的过程控制系统和方法 |
EP2957335B1 (en) * | 2014-06-16 | 2020-05-27 | EMD Millipore Corporation | Single-pass filtration systems and processes |
EP4144434B1 (en) * | 2014-06-16 | 2024-04-17 | EMD Millipore Corporation | Single-pass filtration systems and processes |
WO2015195453A2 (en) * | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Methods for increasing the capacity of flow-through processes |
WO2015195452A2 (en) * | 2014-06-16 | 2015-12-23 | Emd Millipore Corporation | Single-pass filtration systems and processes |
JP6339674B2 (ja) | 2014-06-25 | 2018-06-06 | イー・エム・デイー・ミリポア・コーポレイシヨン | 小型スパイラル型フィルターエレメント、モジュール、およびシステム |
SG11201508665QA (en) | 2014-08-29 | 2016-03-30 | Emd Millipore Corp | Processes For Filtering Liquids Using Single Pass Tangential Flow Filtration Systems AndTangential Flow Filtration Systems With Recirculation of Retentate |
WO2016033546A1 (en) | 2014-08-29 | 2016-03-03 | Emd Millipore Corporation | Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
CN107206070B (zh) | 2014-10-23 | 2022-01-18 | 美国安进公司 | 降低药物制剂的粘度 |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CA2999118C (en) * | 2015-09-22 | 2022-06-14 | Pfizer Inc. | Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method |
JP7106523B2 (ja) * | 2016-08-16 | 2022-07-26 | ジェンザイム・コーポレーション | 組換え治療用タンパク質を含む流体を処理する方法およびその使用 |
EP3500588A1 (en) * | 2016-08-17 | 2019-06-26 | Boehringer Ingelheim International GmbH | Process for the preparation of highly concentrated liquid formulations containing biomolecules |
EA201990998A1 (ru) | 2016-10-21 | 2019-11-29 | Фармацевтические составы и способы их получения | |
JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
CN107952280A (zh) * | 2017-11-28 | 2018-04-24 | 安徽东方帝维生物制品股份有限公司 | 一种兽用疫苗无菌超滤浓缩装置及方法 |
KR20190079530A (ko) * | 2017-12-27 | 2019-07-05 | (주)셀트리온 | 투석 여과 방법 |
AU2019250882A1 (en) * | 2018-04-12 | 2020-11-05 | Amgen Inc. | Methods for making stable protein compositions |
WO2019213567A1 (en) * | 2018-05-04 | 2019-11-07 | Genzyme Corporation | Perfusion bioreactor with filtration systems |
US20210308265A1 (en) * | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
US20210171573A1 (en) * | 2018-08-14 | 2021-06-10 | Bristol-Myers Squibb Company | Improved protein recovery |
TW202043253A (zh) * | 2019-01-28 | 2020-12-01 | 美商安進公司 | 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程 |
PT3791395T (pt) * | 2019-07-31 | 2021-09-22 | Catalent Uk Swindon Zydis Ltd | Medidor de fluxo de densidade para dosagem de formulação farmacêutica |
CN111018968B (zh) * | 2019-12-16 | 2021-07-27 | 兴盟生物医药(苏州)有限公司 | 一种通过超滤浓缩制备高浓度抗体制剂的方法 |
JP7338527B2 (ja) * | 2020-03-19 | 2023-09-05 | 東レ株式会社 | 体液検体中のアレルゲン特異的IgE抗体の検出方法 |
CN111944046B (zh) * | 2020-08-28 | 2021-04-09 | 江苏荃信生物医药有限公司 | 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法 |
EP4225770A1 (en) * | 2020-10-05 | 2023-08-16 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
AU2021381439A1 (en) | 2020-11-23 | 2023-06-22 | Abec, Inc. | Filtration systems,components and methods |
CN114014929B (zh) * | 2021-11-04 | 2022-07-19 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法 |
TW202342068A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 製備高濃度液體原料藥之方法 |
CN115261193A (zh) * | 2022-05-31 | 2022-11-01 | 利穗科技(苏州)有限公司 | 一种生物制品浓缩系统及其工艺 |
WO2024012364A1 (en) * | 2022-07-12 | 2024-01-18 | Beigene Switzerland Gmbh | Preparation methods for a highly concentrated pd1 antibody solution by ultrafiltration/diafiltration (uf/df) |
US12030959B1 (en) | 2023-07-05 | 2024-07-09 | Genentech, Inc. | Anti-IgE antibody therapy for multiple food allergies |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5625616B2 (da) | 1973-10-08 | 1981-06-13 | ||
FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
US4374763A (en) | 1979-09-17 | 1983-02-22 | Morishita Pharmaceutical Co., Ltd. | Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IN161706B (da) * | 1983-10-05 | 1988-01-16 | Solco Basel Ag | |
US4786501A (en) | 1985-07-15 | 1988-11-22 | International Minerals & Chemical Corp. | Cylindrical implants for the controlled release of growth hormones |
US4756696A (en) | 1985-12-06 | 1988-07-12 | Amp Incorporated | Solder joint inspection feature for surface mount connectors |
GB8628104D0 (en) * | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
JPS6485829A (en) | 1987-09-29 | 1989-03-30 | Aisin Aw Co | Transmission for four-wheel drive vehicle |
JPH01268646A (ja) | 1988-04-20 | 1989-10-26 | Meiji Milk Prod Co Ltd | 抗腫瘍剤 |
US4897465A (en) | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5177194A (en) * | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
NL9001650A (nl) | 1990-07-19 | 1992-02-17 | Ver Coop Melkind | Werkwijze voor de bereiding van een melkeiwit-isolaat. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
US5256294A (en) | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
JP2907603B2 (ja) * | 1991-09-09 | 1999-06-21 | 雪印乳業株式会社 | 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品 |
US6270757B1 (en) | 1994-04-21 | 2001-08-07 | Genetics Institute, Inc. | Formulations for IL-11 |
US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5707678A (en) | 1995-04-12 | 1998-01-13 | Galagen Inc. | Method for microfiltration of milk or colostral whey |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
CN102416176A (zh) * | 1995-07-27 | 2012-04-18 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白质制剂 |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
KR20010030665A (ko) | 1997-09-22 | 2001-04-16 | 세프라겐 코포레이션 | 유장 단백질의 순차적 분리법 및 그의 제제 |
RU2140287C1 (ru) | 1998-08-25 | 1999-10-27 | Государственное унитарное предприятие "Иммунопрепарат" | Способ получения альбумина |
WO2000024266A2 (en) | 1998-10-26 | 2000-05-04 | Galagen, Inc. | Soy and immunoglobulin compositions |
UY26236A1 (es) | 1999-07-07 | 2000-10-31 | New Zeland Co Operative Dairy | Metodos para obtener aislados de proteina y concentrados de calostro |
AU2001277781A1 (en) * | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
ES2332402T5 (es) * | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
ES2184594B1 (es) | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
ES2351786T3 (es) * | 2001-11-13 | 2011-02-10 | Genentech, Inc. | Formulaciones con ligando apo2/trail y usos de las mismas. |
EP1551875A4 (en) * | 2002-06-21 | 2006-06-28 | Biogen Idec Inc | TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF |
JP4500683B2 (ja) * | 2002-11-01 | 2010-07-14 | バイエル・ヘルスケア・エルエルシー | 巨大分子濃縮方法 |
GB0229444D0 (en) | 2002-12-18 | 2003-01-22 | Royal Free Hampstead Nhs Trust | Diagnostic method and assay kit |
JP2006515227A (ja) * | 2003-02-24 | 2006-05-25 | ジーティーシー バイオセラピューティックス インコーポレイテッド | 十字流濾過の方法およびそのための装置 |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
US20070244305A1 (en) | 2004-01-30 | 2007-10-18 | Suomen Punainen Risti Veripalvelu | Process for The Manufacture of Virus Safe Immunoglobulin |
US20060051347A1 (en) * | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
JP6044754B2 (ja) | 2012-01-19 | 2016-12-14 | 株式会社ジェイテクト | クラッチプレートおよびその製造方法 |
-
2005
- 2005-09-06 US US11/220,362 patent/US20060051347A1/en not_active Abandoned
- 2005-09-07 MY MYPI20054224A patent/MY162525A/en unknown
- 2005-09-07 MY MYPI20104600 patent/MY150549A/en unknown
- 2005-09-07 TW TW094130719A patent/TWI372630B/zh active
- 2005-09-08 LT LTEP22178156.0T patent/LT4104859T/lt unknown
- 2005-09-08 MX MX2007002812A patent/MX2007002812A/es not_active Application Discontinuation
- 2005-09-08 EP EP22178117.2A patent/EP4108259B1/en active Active
- 2005-09-08 AU AU2005285243A patent/AU2005285243C1/en active Active
- 2005-09-08 CN CN200580038351.0A patent/CN101056885B/zh active Active
- 2005-09-08 KR KR1020127030933A patent/KR101528970B1/ko active IP Right Review Request
- 2005-09-08 PT PT100099142T patent/PT2292636T/pt unknown
- 2005-09-08 ZA ZA200701626A patent/ZA200701626B/xx unknown
- 2005-09-08 LT LTEP22178117.2T patent/LT4108259T/lt unknown
- 2005-09-08 SI SI200532316T patent/SI2292636T1/sl unknown
- 2005-09-08 RU RU2007110534/13A patent/RU2390524C2/ru active
- 2005-09-08 EP EP22178156.0A patent/EP4104859B1/en active Active
- 2005-09-08 SI SI200532312T patent/SI3805248T1/sl unknown
- 2005-09-08 SI SI200531932T patent/SI1786830T1/sl unknown
- 2005-09-08 KR KR1020077007862A patent/KR20070109975A/ko not_active Application Discontinuation
- 2005-09-08 DK DK05806393.4T patent/DK1786830T3/da active
- 2005-09-08 LT LTEP10009914.2T patent/LT2292636T/lt unknown
- 2005-09-08 FI FIEP10009914.2T patent/FI2292636T3/fi active
- 2005-09-08 MX MX2012011125A patent/MX342788B/es unknown
- 2005-09-08 WO PCT/US2005/031844 patent/WO2006031560A2/en active Application Filing
- 2005-09-08 NZ NZ553239A patent/NZ553239A/en unknown
- 2005-09-08 LT LTEP20200642.5T patent/LT3805248T/lt unknown
- 2005-09-08 PT PT58063934T patent/PT1786830E/pt unknown
- 2005-09-08 CN CN2012103764183A patent/CN102911268A/zh active Pending
- 2005-09-08 HU HUE10009914A patent/HUE065025T2/hu unknown
- 2005-09-08 SG SG2011088622A patent/SG177161A1/en unknown
- 2005-09-08 ES ES22178117T patent/ES2975166T3/es active Active
- 2005-09-08 ES ES10009914T patent/ES2968070T3/es active Active
- 2005-09-08 EP EP20200642.5A patent/EP3805248B1/en active Active
- 2005-09-08 DK DK22178117.2T patent/DK4108259T3/da active
- 2005-09-08 JP JP2007531302A patent/JP5210633B2/ja active Active
- 2005-09-08 PT PT202006425T patent/PT3805248T/pt unknown
- 2005-09-08 EP EP10009914.2A patent/EP2292636B9/en active Active
- 2005-09-08 EP EP05806393.4A patent/EP1786830B1/en not_active Revoked
- 2005-09-08 BR BRPI0515649A patent/BRPI0515649B8/pt active IP Right Grant
- 2005-09-08 ES ES20200642T patent/ES2942574T3/es active Active
- 2005-09-08 CN CN201510468312.XA patent/CN104961797B/zh active Active
- 2005-09-08 HU HUE20200642A patent/HUE061899T2/hu unknown
- 2005-09-08 ES ES05806393.4T patent/ES2528541T3/es active Active
- 2005-09-08 SI SI200532317T patent/SI4108259T1/sl unknown
- 2005-09-08 FI FIEP20200642.5T patent/FI3805248T3/fi active
- 2005-09-08 DK DK20200642.5T patent/DK3805248T5/da active
- 2005-09-08 PL PL20200642.5T patent/PL3805248T3/pl unknown
- 2005-09-08 PL PL10009914.2T patent/PL2292636T3/pl unknown
- 2005-09-08 PL PL22178117.2T patent/PL4108259T3/pl unknown
- 2005-09-08 DK DK10009914.2T patent/DK2292636T3/da active
- 2005-09-08 DK DK22178156.0T patent/DK4104859T3/da active
- 2005-09-08 FI FIEP22178156.0T patent/FI4104859T3/fi active
- 2005-09-08 PL PL05806393T patent/PL1786830T3/pl unknown
- 2005-09-08 PT PT221781172T patent/PT4108259T/pt unknown
- 2005-09-08 CA CA2577317A patent/CA2577317C/en active Active
- 2005-09-09 AR ARP050103779A patent/AR050641A1/es active IP Right Grant
- 2005-09-09 GT GT200500254A patent/GT200500254A/es unknown
- 2005-09-09 PE PE2005001049A patent/PE20060816A1/es active IP Right Grant
-
2006
- 2006-09-29 US US11/537,577 patent/US20070237762A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181372A patent/IL181372A/en active IP Right Grant
- 2007-02-23 TN TNP2007000069A patent/TNSN07069A1/en unknown
- 2007-02-28 EC EC2007007282A patent/ECSP077282A/es unknown
- 2007-03-16 NO NO20071432A patent/NO333660B1/no unknown
- 2007-04-06 MA MA29809A patent/MA28991B1/fr unknown
- 2007-06-27 HK HK07106910.7A patent/HK1101249A1/xx not_active IP Right Cessation
-
2009
- 2009-02-19 US US12/389,140 patent/US20090214522A1/en not_active Abandoned
-
2011
- 2011-11-24 JP JP2011256451A patent/JP5426641B2/ja active Active
- 2011-12-08 IL IL216851A patent/IL216851A0/en unknown
-
2014
- 2014-04-21 US US14/257,907 patent/US10370456B2/en active Active
-
2016
- 2016-04-05 HK HK16103797.1A patent/HK1215869A1/zh unknown
-
2020
- 2020-09-10 US US17/017,465 patent/US20210095050A1/en active Pending
-
2022
- 2022-11-01 US US17/978,913 patent/US11767370B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2292636T3 (da) | Fremgangsmåde til opkoncentrering af antistoffer og terapeutiske produkter deraf | |
DK3345927T3 (da) | Humant monoklonalt antistof Human CD134 (OX40) og fremgangsmåder til frembringelse og anvendelse deraf | |
DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
DK1853271T3 (da) | Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme | |
DK1679058T3 (da) | Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme | |
DK1756544T3 (da) | Diagnoseindretninger indeholdende fluider og fremgangsmåder til fremstilling | |
DK1641832T3 (da) | Fremgangsmåde til fremstilling af fiberholdig pektin og produkter og anvendelser heraf | |
DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
DK1922309T3 (da) | N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf | |
DK1844074T3 (da) | Humane antistoffer og proteiner | |
NO20033387L (no) | Modifiserte antistoffer og fremgangsmåter for anvendelse | |
DK1740197T3 (da) | Prolyl-endopeptidease (PEP) og glutamin-endoprotease til behandlingen af cøliaki | |
DK1755743T3 (da) | Beta-hydroxybutyrat og derivater til behandling af depression og angst | |
DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
DK1965763T3 (da) | Stabile enzympræparater og fremgangsmåder til anvendelse heraf | |
DK1663298T3 (da) | Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner | |
DK1877090T3 (da) | Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf | |
DK1862158T5 (da) | Farmaceutisk sammensætning til behandling af depression og fremgangsmåde til fremstilling deraf | |
IS8597A (is) | Samsetningar rísedrónats og aðferðir við notkun þess | |
DK1817055T3 (da) | Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse heraf | |
DK1919290T3 (da) | Fremgangsmåder og produkter til behandling af sygdomme | |
DK1750713T3 (da) | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner | |
DK2144555T4 (da) | Indretning og fremgangsmåde til transkutan bestemmelse af blodgasser | |
DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
DK1788881T3 (da) | Fremgangsmåder og produkter til brødfremstilling |